Kesimpta costs up to $90,000/year without insurance. Learn about the Kesimpta Access Card, patient assistance programs, and other ways to save in 2026.
Let's start with the number that keeps MS patients up at night: Kesimpta (Ofatumumab) has a list price of approximately $6,800 to $7,500 per monthly injection. That's roughly $82,000 to $90,000 per year.
If you've just seen that number for the first time, take a breath. The reality is that most patients don't pay anywhere near the list price — but only if they know where to look and what programs to use. This guide breaks down every major way to reduce your out-of-pocket cost for Kesimpta in 2026.
Without insurance or financial assistance, you'd be looking at the full list price:
These are among the highest costs in the MS treatment landscape. However, very few patients actually pay the list price thanks to insurance coverage and financial assistance programs.
The single most impactful savings program for Kesimpta is the Kesimpta Access Card, offered directly by manufacturer Novartis.
Visit start.kesimpta.com or call 1-855-KESIMPTA (1-855-537-4678). Your neurologist's office can also help you enroll.
If you're uninsured or underinsured and can't afford Kesimpta, the Novartis Patient Assistance Foundation may provide the medication at no cost.
Because Kesimpta is a specialty biologic without a generic equivalent, traditional pharmacy discount cards (like GoodRx or SingleCare) have limited utility. Here's the reality:
The bottom line: for Kesimpta, the Kesimpta Access Card from Novartis is far more valuable than any third-party discount card.
In addition to the manufacturer programs, several independent organizations may be able to help with MS medication costs:
Your neurologist's MS coordinator or patient navigator can be your best ally in reducing costs. They often know which programs have funding available, can complete applications on your behalf, and may have relationships with specialty pharmacies that offer additional support services.
If your insurance denies coverage for Kesimpta, don't give up. The appeals process often results in approval when supported by strong clinical documentation from your neurologist. While appealing, the Kesimpta Access Card's free medication program can keep you on therapy.
If you're on Medicare, you may qualify for the Extra Help / Low-Income Subsidy (LIS) program, which reduces prescription drug costs under Part D. Visit ssa.gov/medicare/part-d-extra-help or call 1-800-772-1213.
Many states offer pharmaceutical assistance programs that can help cover the cost of expensive medications. Your state's Department of Health or Aging can provide information on available programs.
Kesimpta's list price of $82,000–$90,000 per year is daunting, but the actual out-of-pocket cost for most patients is dramatically lower — and often $0 — when the right programs are used. The Kesimpta Access Card is the most important tool for commercially insured patients, while the Novartis Patient Assistance Foundation serves as a safety net for those without adequate coverage.
Don't navigate this alone. Your neurologist's office, the Novartis support team, and independent foundations like the National MS Society all exist to help you access the treatment you need at a cost you can manage.
If you're also having trouble finding Kesimpta in stock, check out our guide on how to find Kesimpta near you. And for the latest on availability, read our 2026 shortage update.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
